IP Library Granted Patent US 11,802,291
Granted Patent B2
US 11,802,291 · App. 16/299,456 · Granted Oct 31, 2023

Recombinant virus products and methods for inhibition of expression of DUX4

Inventors: Scott Quenton Harper (Powell, OH); Jian Liu (Los Angeles, CA); Sara Coppens (Columbus, OH); Lindsay Wallace (Columbus, OH)
Assignee: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
C12N15/86C12N15/113C12N2310/11C12N2310/141C12N2320/30C12N2330/51C12N2750/00032C12N2750/14132C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,802,291
App. No.
16/299,456
Granted
Oct 31, 2023
Kind
B2
Abstract

The present invention relates to RNA interference-based methods for inhibiting the expression of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy.

Claims (66)

1. A method of treating a subject suffering from a facioscapulohumeral muscular dystrophy associated with overexpression of DUX4 in the subject, the method comprising administering intramuscularly to the subject a recombinant adeno-associated virus comprising a DNA operably linked to a muscle specific control element, the DNA encoding a DUX4 miRNA comprising an miRNA antisense guide strand, wherein the miRNA antisense guide strand consists of the nucleotide sequence of

SEQ ID NO: 8482,

SEQ ID NO: 8372,

SEQ ID NO: 8371,

SEQ ID NO: 8370,

SEQ ID NO: 8367,

SEQ ID NO: 8366,

SEQ ID NO: 8365,

SEQ ID NO: 8219,

SEQ ID NO: 8218,

SEQ ID NO: 8152,

SEQ ID NO: 8147,

SEQ ID NO: 8145,

SEQ ID NO: 7397,

SEQ ID NO: 7396,

SEQ ID NO: 7395,

SEQ ID NO: 7108,

SEQ ID NO: 7107,

SEQ ID NO: 7106,

SEQ ID NO: 6633,

SEQ ID NO: 6631,

SEQ ID NO: 6622,

SEQ ID NO: 6619,

SEQ ID NO: 6609,

SEQ ID NO: 6608,

SEQ ID NO: 6568,

SEQ ID NO: 6561 or

SEQ ID NO: 6560, and

wherein the DUX4 miRNA inhibits expression of the DUX4 gene in the subject.

2. The method of claim 1 , wherein the recombinant adeno-associated virus lacks rep and cap genes.

3. The method of claim 1 , wherein the adenovirus recombinant adeno-associated virus (rAAV) is rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10 or rAAV11.

4. The method of claim 3 , wherein the rAAV is rAAV6.

5. A method of inhibiting DUX4 expression by a cell comprising the DUX4 gene, the method comprising administering to the cell a recombinant adeno-associated virus comprising a DNA operably linked to a tissue specific control element, the DNA encoding a DUX4 miRNA comprising an miRNA antisense guide strand, wherein the miRNA antisense guide strand consists of the nucleotide sequence of

SEQ ID NO: 8482,

SEQ ID NO: 8372,

SEQ ID NO: 8371,

SEQ ID NO: 8370,

SEQ ID NO: 8367,

SEQ ID NO: 8366,

SEQ ID NO: 8365,

SEQ ID NO: 8219,

SEQ ID NO: 8218,

SEQ ID NO: 8152,

SEQ ID NO: 8147,

SEQ ID NO: 8145,

SEQ ID NO: 7397,

SEQ ID NO: 7396,

SEQ ID NO: 7395,

SEQ ID NO: 7108,

SEQ ID NO: 7107,

SEQ ID NO: 7106,

SEQ ID NO: 6633,

SEQ ID NO: 6631,

SEQ ID NO: 6622,

SEQ ID NO: 6619,

SEQ ID NO: 6609,

SEQ ID NO: 6608,

SEQ ID NO: 6568,

SEQ ID NO: 6561 or

SEQ ID NO: 6560, and

wherein the DUX4 miRNA inhibits expression of the DUX4 gene in the cell.

6. The method of claim 5 , wherein the recombinant adeno-associated virus lacks rep and cap genes.

7. The method of claim 5 , wherein the recombinant adeno-associated virus (rAAV) is rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10 or rAAV11.

8. The method of claim 7 , wherein the rAAV is rAAV6.

9. The method of claim 5 , wherein the cell is a muscle cell.

10. The method of claim 5 , wherein the tissue specific control element is muscle specific.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NUMBER PCT/US14/47999 FILED 07/24/2014 SHOULD BE PCT/US12/47999 FILED 07/24/2012 PREVIOUSLY RECORDED ON REEL 063643 FRAME 0786. ASSIGNOR(S) HEREBY CONFIRMS THE THE CORRECT SERIAL NUMBER AND ASSIGNMENT DOC ID 507906702. Recorded May 24, 2023
From: NATIONWIDE CHILDREN'S HOSPITAL, INC.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 063743/0208 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2023
From: NATIONWIDE CHILDREN'S HOSPITAL, INC.
To: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 063643/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2019
From: HARPER, SCOTT Q.; LIU, JIAN; COPPENS, SARA; WALLACE, LINDSAY
To: NATIONWIDE CHILDREN'S HOSPITAL, INC.
Reel/Frame 048637/0768 →
Continuity (4)
Division 15295591 · Oct 17, 2016
Continuation 14234413
Provisional Application 61511319 · Jul 25, 2011
Related Publication 20190300903A1 · Oct 3, 2019